|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM160924162 |
| 003 |
DE-627 |
| 005 |
20231223091114.0 |
| 007 |
tu |
| 008 |
231223s2006 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0537.xml
|
| 035 |
|
|
|a (DE-627)NLM160924162
|
| 035 |
|
|
|a (NLM)16500150
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Zachou, Kalliopi
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Presence of high avidity anticardiolipin antibodies in patients with autoimmune cholestatic liver diseases
|
| 264 |
|
1 |
|c 2006
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 31.05.2006
|
| 500 |
|
|
|a Date Revised 17.11.2011
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a We studied the prevalence and clinical significance of anticardiolipin antibodies (aCL) in primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) as similar data are missing. Ninety-nine PBC patients, 41 PSC, 228 HCV, 50 HBV, 111 with other non-viral and non-autoimmune liver disorders and 267 healthy were investigated. In order to evaluate the avidity of aCL, urea 2 M was used. IgG and/or IgM aCL were detected in 40% of PBC and PSC patients, in 26.2% of disease controls (P < 0.05) and 2.25% of healthy (P < 0.05). In PBC, IgG aCL associated with presence of cirrhosis, increased Mayo risk score and thrombocytopenia, while in PSC with longer disease duration and biochemical activity. Anti-beta2-GPI was detected in only three patients. Both in PBC and PSC, resistance of aCL to urea was high, similar to that observed in antiphospholipid syndrome (APS). We demonstrated a significantly higher prevalence of aCL in PBC and PSC compared to other liver diseases and healthy. aCL were associated with more severe disease in PBC and biochemical activity in PSC, but they rather seem to be "non-pathogenic" (co-factor-independent). However, their avidity was comparable with that of APS, indicating the need for prospective studies in order to address whether aCL in PBC and PSC may contribute to APS development or the progression of hepatic disease
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
7 |
|a Antibodies, Anticardiolipin
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin G
|2 NLM
|
| 650 |
|
7 |
|a Immunoglobulin M
|2 NLM
|
| 700 |
1 |
|
|a Liaskos, Christos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Rigopoulou, Eirini
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gabeta, Stela
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Papamichalis, Panagiotis
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Gatselis, Nikolaos
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Georgiadou, Sarah
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Dalekos, George N
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 119(2006), 2 vom: 13. Mai, Seite 203-12
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:119
|g year:2006
|g number:2
|g day:13
|g month:05
|g pages:203-12
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 119
|j 2006
|e 2
|b 13
|c 05
|h 203-12
|